{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-179418","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.145633+00:00","generated_at":"2026-05-17T13:55:04.339486+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aura Biosciences Q2 2025 net loss $27.0M; cash $177.3M; Phase 3 CoMpass nearing enrollment end","bullets":["Net loss $27.0M in Q2 2025 vs $20.3M in Q2 2024; R&D expenses rose to $22.9M from $16.9M.","Cash and marketable securities $177.3M; $75M equity financing closed; cash runway into first half 2027.","Phase 3 CoMpass trial in early choroidal melanoma actively enrolling; >240 patients pre-screened; enrollment may complete by end of 2025.","Phase 1b/2 NMIBC trial actively enrolling; new bel-sar formulation patent filed for convenient in-office use.","Phase 2 trial in metastases to choroid protocol amended to include all solid tumors; initial data expected 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-179418","json":"https://secwatch.observer/filing/0001193125-25-179418.json","markdown":"https://secwatch.observer/filing/0001193125-25-179418.md","text":"https://secwatch.observer/filing/0001193125-25-179418.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000119312525179418/0001193125-25-179418-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000119312525179418/aura-20250813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:55:04.339486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}